Creating targeted drugs to treat advanced prostate cancer
Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancer
This study is looking at new drugs that target a specific protein involved in cancer growth, hoping to make treatments for advanced prostate cancer safer and more effective, especially when combined with current immunotherapy options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11227326 on NIH RePORTER |
What this research studies
This research aims to develop new drugs that specifically inhibit a protein called Hsp90β, which is important for cancer cell growth. By focusing on this specific protein, the researchers hope to reduce side effects commonly seen with broader treatments. The study will test these new inhibitors in prostate cancer models to see if they can not only stop cancer cell growth but also improve the effectiveness of existing immunotherapy treatments. Patients may benefit from a more effective and safer treatment option for advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced prostate cancer, particularly those who have developed resistance to current therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting Hsp90 inhibitors, indicating potential for success with this novel approach.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Blagg, Brian S J — University of Notre Dame
- Study coordinator: Blagg, Brian S J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.